Add-on Study on Solidarity Trial Plus in Nepal

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Proposal for Sub-Study to be conducted with the WHO Solidarity Plus Trial:

Apart from the data been collected as per the WHO Solidarity Trial Plus protocol, Nepal Health Research Council will conduct a sub-study to evaluate some components which are felt to be important in the local context but have not been included as part of the Solidarity Trial Plus. Rather that conducting a separate study, the following components can be evaluated by collecting additional data as a part of sub-study in the local context.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nepal Health Research Council
• Collaborator: World Health Organization
• Treatments: Artesunate; Infliximab

Criteria

Inclusion Criteria:

• Recently hospitalized (or already in hospital) with laboratory-confirmed COVID

• In the view of their doctors, no contra-indication to any potentially relevant study drug.

• Voluntary Participation

Exclusion Criteria:

• In the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra-indicated (eg, because of patient characteristics, chronic liver or heart disease, or some concurrent medication).

• If expected to be transferred within 72 hours